Rapid skin improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0
|
作者：
Simpson, Eric L. [1 ]
Warren, Richard B. [2 ]
Eichenfield, Lawrence F. [3 ,4 ]
Katoh, Norito [5 ]
Hu, Xiaofei [6 ]
Zeng, Jiewei [6 ]
Calimlim, Brian M. [6 ]
Tenorio, Allan R. [6 ]
Teixeira, Henrique D. [6 ]
De Bruin-Weller, Marjolein [7 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Dermatol Ctr, Manchester, Lancs, England
[3] Univ Calif San Diego, Sch Med, Dept Dermatol, San Diego, CA USA
[4] Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA USA
[5] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kyoto, Japan
[6] AbbVie Inc, N Chicago, IL USA
[7] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27915
引用
收藏
页码：AB167 / AB167
页数：1
相关论文
共 50 条
  • [41] Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)
    Simpson, Eric L.
    Costanzo, Antonio
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Chu, Alvina D.
    Wu, Tianshuang
    Eyerich, Kilian
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II30 - II31
  • [42] Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies
    Kabashima, K.
    Matsumura, T.
    Komazaki, H.
    Kawashima, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 642 - 651
  • [43] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, J. I.
    Thyssen, J. P.
    Rosmarin, D.
    Pink, A. E.
    Calimlim, B. M.
    Teixeira, H. D.
    Hu, X.
    Yang, Y.
    Thaci, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E125
  • [44] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021)
    Reich, K.
    Teixeira, H. D.
    de Bruin-Weller, M.
    LANCET, 2021, 398 (10302): : 746 - 746
  • [45] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021)
    Reich, K.
    Teixeira, H. D.
    de Bruin-Weller, M.
    LANCET, 2021, 397 (10292): : 2336 - 2336
  • [46] Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
    Magnolo, Nina
    Cameron, Michael C.
    Shahriari, Mona
    Geng, Bob
    Calimlim, Brian M.
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Zhang, Shiyu
    Sanchez, Cristina Sancho
    Altman, Katherine
    Langley, Richard G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [47] Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids
    Guttman-Yassky, E.
    Weidinger, S.
    Silverberg, J.
    Gooderham, M.
    Thyssen, J.
    Irvine, A.
    Elmaraghy, H.
    Natalie, C.
    Hu, C.
    Pierce, E.
    Gil, E. G.
    Simpson, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S348 - S348
  • [48] Open Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)
    Tanaka, Toshiaki
    Sasaki, Takuya
    Ikeda, Kimitoshi
    Liu, Jianzhong
    Tenorio, Allan R.
    Ohya, Yukihiro
    WORLD ALLERGY ORGANIZATION JOURNAL, 2022, 15 (09):
  • [49] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
    Simpson, Eric L.
    Prajapati, Vimal H.
    Leshem, Yael A.
    Chovatiya, Raj
    de Bruin-Weller, Marjolein S.
    Staender, Sonja
    Pink, Andrew E.
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique
    Ladizinski, Barry
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Liu, Meng
    Grada, Ayman
    Platt, Andrew M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
  • [50] Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
    Blauvelt, Andrew
    Ladizinski, Barry
    Prajapati, Vimal H.
    Laquer, Vivian
    Fischer, Alison
    Eisman, Samantha
    Hu, Xiaofei
    Wu, Tianshuang
    Calimlim, Brian M.
    Kaplan, Blair
    Liu, Yingyi
    Teixeira, Henrique D.
    Liu, John
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 478 - 485
12345